Especially on X, algorithmic culture is characterized by ceaseless iteration: Everything that’s happening is piled atop all ...
Leveraging modular gene editors and new regulatory pathways, Aurora will develop and commercialize therapies that can be rapidly tailored to many rare variants -- Founded by CRISPR pioneers Jennifer ...
Keep up to date with the most important stories and the best deals, as picked by the PC Gamer team.
Machine learning is reshaping the way portfolios are built, monitored, and adjusted. Investors are no longer limited to ...
Between Choice and Fate at Batsford Gallery has a very charged yet subtle quality. The gallery’s atmosphere seems more akin ...
Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...
With a single click, unlock detailed, AI-assisted insights pulled from hundreds of financial data points instantly.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback